MedPath

Fenofibrate

Generic Name
Fenofibrate
Brand Names
Antara, Cholib, Fenoglide, Fenomax, Lipidil Supra, Lipofen, Tricor, Triglide
Drug Type
Small Molecule
Chemical Formula
C20H21ClO4
CAS Number
49562-28-9
Unique Ingredient Identifier
U202363UOS
Background

Fenofibrate is a fibric acid derivative like clofibrate and gemfibrozil. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.

Fenofibrate was granted FDA approval on 31 December 1993.

Indication

Fenofibrate is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C adults with primary hypercholesterolemia or mixed dyslipidemia. Fenofibrate is also indicated to treat adults with severe hypertriglyceridemia.

Associated Conditions
Mixed Dyslipidemias, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Severe Fredrickson Type IV Hypertriglyceridemia, Severe Fredrickson Type V Hypertriglyceridemia
Clinical Trials
Related News

Study to Assess Tricor Therapy Effectiveness in Patients With Metabolic Syndrome (TRISTAN)

Completed
Conditions
Hypertriglyceridemia
Metabolic Syndrome
Interventions
First Posted Date
2020-12-02
Last Posted Date
2021-12-15
Lead Sponsor
Abbott
Target Recruit Count
1000
Registration Number
NCT04650152
Locations
🇷🇺

Clinical hospital, Samara, Russian Federation

🇷🇺

Clinical Diagnostic Centre, Bryansk, Russian Federation

🇷🇺

Dispensary, Krasnoyarsk, Russian Federation

and more 39 locations

Fenofibrate Therapy in Pathological Unconjugated Hyperbilirubinemia in Full Term Infants

Not Applicable
Completed
Conditions
Neonatal Jaundice
Interventions
Drug: Placebo
First Posted Date
2020-06-05
Last Posted Date
2020-06-05
Lead Sponsor
Mansoura University
Registration Number
NCT04418180

Effect of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients

Phase 4
Conditions
Diabetic Retinopathy
Interventions
Drug: Omega 3 fatty acid
First Posted Date
2019-10-25
Last Posted Date
2020-01-18
Lead Sponsor
Alaa Hassan ElBaz
Target Recruit Count
80
Registration Number
NCT04140201

Cinical Trial to Explore the Efficacy of Statin/Choline Fenofibrate Combination Therapy vs Statin Monotherapy in Patients With Inadequately Controlled TG Despite Receiving Statin Monotherapy

Phase 4
Conditions
Dyslipidemias
Interventions
First Posted Date
2019-03-14
Last Posted Date
2019-03-15
Lead Sponsor
Daewon Pharmaceutical Co., Ltd.
Target Recruit Count
180
Registration Number
NCT03874260
Locations
🇰🇷

Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si, Korea, Republic of

Effects of Fenofibrate Therapy in Diabetic Nephropathy

Phase 3
Conditions
Diabetes Mellitus
Diabetic Nephropathies
Interventions
First Posted Date
2019-03-11
Last Posted Date
2020-12-14
Lead Sponsor
Singapore General Hospital
Target Recruit Count
300
Registration Number
NCT03869931
Locations
🇸🇬

Singapore General Hospital, Singapore, Singapore

Fenofibrate in Type 2 Diabetes

Phase 4
Completed
Conditions
Diabetes Mellitus, Type II
Interventions
First Posted Date
2019-02-04
Last Posted Date
2023-10-24
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
10
Registration Number
NCT03829514
Locations
🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

Extended Release Niacin and Fenofibrate for the Treatment of Atherogenic Dyslipidemia in Obese Females

Phase 4
Completed
Conditions
Atherogenic Dyslipidemia
Obesity Associated Disorder
Interventions
Other: Therapeutic Lifestyle Changes
Dietary Supplement: Wax Matrix Extended Release Niacin (WMER Niacin)
Other: Placebo
First Posted Date
2018-08-06
Last Posted Date
2024-01-24
Lead Sponsor
Lewai Sharki Abdulaziz, MSc PhD
Target Recruit Count
161
Registration Number
NCT03615534
Locations
🇮🇶

Lewai S Abdulaziz, Baghdad, Iraq

🇮🇶

Al Kindy College of Medicine, University of Baghdad, Baghdad, Iraq

Fibrates in Pediatric Cholestasis

Phase 2
Completed
Conditions
Chronic Cholestasis
Interventions
Drug: Ursogal
First Posted Date
2018-07-13
Last Posted Date
2018-07-17
Lead Sponsor
Hoda A. Atta
Target Recruit Count
50
Registration Number
NCT03586674
Locations
🇪🇬

Dr. Yassin Abdel Ghaffar Charity Center For Liver Diseases & Researches, Cairo, Nasr City, Egypt

🇪🇬

National liver istitute, Shibīn Al Kawm, Egypt

Evaluation of Fenofibrate on Radiation-induced Skin Injury

Not Applicable
Conditions
Radiodermatitis
Interventions
Drug: Saline
First Posted Date
2018-06-15
Last Posted Date
2018-06-15
Lead Sponsor
Second Affiliated Hospital of Soochow University
Target Recruit Count
30
Registration Number
NCT03557983
Locations
🇨🇳

苏州大学, Suzhou, Jiangsu, China

Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease

Phase 2
Completed
Conditions
Huntington Disease
Interventions
Drug: Placebo
First Posted Date
2018-05-03
Last Posted Date
2023-09-28
Lead Sponsor
University of California, Irvine
Target Recruit Count
10
Registration Number
NCT03515213
Locations
🇺🇸

University of California, Irvine, Irvine, California, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy